Taken together, all the results showed that metapristone inhibited the endometrial cancer cell growth in vitro and in vivo through regulating miR-492/Klf5/Nrf1 axis and the cell apoptosis-related signaling pathways (Fig. 5f). Here, NRF1 is linked to endometrial cancer.